Abstract
Background
Mucosal melanomas account for 17% of melanomas, and less than 1% affect the urogenital tract. Primary urethral melanoma is extremely rare; less than 200 cases have been reported so far since it was first described. The clinical presentation is usually delayed, and the prognosis is generally poor.
Case presentation.
An 86-year-old female was referred to urology due to the presence of a three-month-old violaceous mass in the urethral meatus protruding through the vagina. On physical examination, a pedunculated, hyperpigmented, friable, and tender lesion was seen in the urethral meatus bulging between the labia minora. After initial diagnostic studies, the patient was taken to surgical resection of the lesion. The pathology report identified the lesion as a malignant melanoma of the urethra, and staging studies revealed regional lymph node metastases. After discussing the treatment options with the patient, palliative therapy with nivolumab was started. In follow-up at 26 months, the patient had evidence of extensive lymph node involvement, but a conserved performance status and no visceral metastases.
Conclusion
Primary melanoma of the female urethra is an uncommon disease with a poor prognosis. Despite the deficiency in literature regarding its management, it is important to consider patient expectations and preferences when treating this rare disease.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Universidad Nacional de Colombia, Department of Urology, School of Medicine, Bogotá, Colombia (GRID:grid.10689.36) (ISNI:0000 0001 0286 3748); Universidad Nacional de Colombia, Urology Research and Innovation Group, Bogotá, Colombia (GRID:grid.10689.36) (ISNI:0000 0001 0286 3748)
2 Universidad de Antioquia, Department of Urology, School of Medicine, Medellín, Colombia (GRID:grid.412881.6) (ISNI:0000 0000 8882 5269)
3 Fundación Universitaria Sanitas, Department of Urology, School of Medicine, Bogotá, Colombia (GRID:grid.442116.4) (ISNI:0000 0004 0404 9258)
4 Universidad Nacional de Colombia, School of Medicine, Bogotá, Colombia (GRID:grid.10689.36) (ISNI:0000 0001 0286 3748)
5 Universidad Nacional de Colombia, Urology Research and Innovation Group, Bogotá, Colombia (GRID:grid.10689.36) (ISNI:0000 0001 0286 3748); Universidad Nacional de Colombia, Department of Urology, School of Medicine, Bogotá, Colombia (GRID:grid.10689.36) (ISNI:0000 0001 0286 3748)
6 Universidad Nacional de Colombia, Urology Research and Innovation Group, Bogotá, Colombia (GRID:grid.10689.36) (ISNI:0000 0001 0286 3748); Fundación Universitaria Sanitas, Department of Urology, School of Medicine, Bogotá, Colombia (GRID:grid.442116.4) (ISNI:0000 0004 0404 9258)





